95 related articles for article (PubMed ID: 6464166)
1. Antibody-facilitated chimeras. Stem cell allotransplantation using antihost major histocompatibility complex monoclonal antibodies instead of lethal irradiation for host conditioning.
Gambel P; Francescutti LH; Wegmann TG
Transplantation; 1984 Aug; 38(2):152-8. PubMed ID: 6464166
[TBL] [Abstract][Full Text] [Related]
2. Models for the production of stable hematopoietic chimerism across major histocompatibility barriers in adults.
Wegmann TG; Rosovsky J; Carlson GA; Diener E; Drell DW
J Immunol; 1980 Oct; 125(4):1751-7. PubMed ID: 7410851
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation across major histocompatability barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants.
Vallera DA; Soderling CC; Kersey JH
J Immunol; 1982 Feb; 128(2):871-5. PubMed ID: 6172513
[TBL] [Abstract][Full Text] [Related]
4. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
5. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
7. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
9. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
Shizuru JA; Jerabek L; Edwards CT; Weissman IL
Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex class II expression is required for posttransplant immunological but not hemopoietic reconstitution in mice.
Huss R; Beckham C; Storb R; Deeg HJ
Transplantation; 1994 Dec; 58(12):1366-71. PubMed ID: 7809930
[TBL] [Abstract][Full Text] [Related]
11. Requirement of major histocompatibility complex-compatible microenvironment for spleen colony formation (CFU-S on day 12 but not on day 8).
Sugiura K; Inaba M; Hisha H; Borisov K; Sardiña EE; Good RA; Ikehara S
Stem Cells; 1997; 15(6):461-8. PubMed ID: 9402659
[TBL] [Abstract][Full Text] [Related]
12. Bidirectional blockade of CD4 and major histocompatibility complex class II molecules: an effective immunosuppressive treatment in the mouse heart transplantation model.
Ito H; Hamano K; Fukumoto T; Wood KJ; Esato K
J Heart Lung Transplant; 1998 May; 17(5):460-9. PubMed ID: 9628564
[TBL] [Abstract][Full Text] [Related]
13. Essential requirement of I-A region-identical host bone marrow or bone marrow-derived cells for tumor neutralization by primed L3T4+ T cells.
Ozawa H; Iwaguchi T; Kataoka T
J Immunol; 1987 Dec; 139(11):3896-901. PubMed ID: 2960743
[TBL] [Abstract][Full Text] [Related]
14. Influence of major histocompatibility complex H-2LD class I molecules on spleen colony-forming units.
Tange T; Ahmed-Ansari A; Hansen T; Tse HY
J Immunol; 1988 Feb; 140(3):700-4. PubMed ID: 3276777
[TBL] [Abstract][Full Text] [Related]
15. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
16. Ia-restricted B-B cell interaction. I. The MHC haplotype of bone marrow cells present during B cell ontogeny dictates the self-recognition specificity of B cells in the polyclonal B cell activation by a B cell differentiation factor, B151-TRF2.
Ono S; Takahama Y; Hamaoka T
J Immunol; 1987 Nov; 139(10):3213-23. PubMed ID: 3316381
[TBL] [Abstract][Full Text] [Related]
17. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
[TBL] [Abstract][Full Text] [Related]
18. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
